News from immune design

( OTC-PINK:GIMU)

Jun 05, 2014, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent

 Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic...

May 27, 2014, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design's GLAAS™ Discovery Platform Used in MEDI7510 Phase 1 Trial for Respiratory Syncytial Virus

 Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic...

Mar 18, 2014, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Appoints Franklin M. Berger to Board of Directors

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic...

Mar 06, 2014, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Appoints William Ringo to Board of Directors

 Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other...

Jan 27, 2014, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G100, an Investigational Immuno-Oncology Agent

Immune Design, a clinical-stage biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic...

Oct 30, 2013, 07:30 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Raises Up to $49 Million Series C Financing

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today...

Sep 26, 2013, 08:00 ET
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. For more information, visit www.immunedesign.com.  (PRNewsFoto/Immune Design)

Immune Design Appoints Stephen R. Brady Chief Business Officer

 Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions,...

Dec 02, 2011, 10:12 ET
Immune Design Corp.  (PRNewsFoto/Immune Design Corp.)

Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer

 Immune Design Corp. announced today that Wayne R. Gombotz, Ph.D. has joined the company as its new Chief Development Officer....

Oct 26, 2011, 07:00 ET
Immune Design Corp.  (PRNewsFoto/Immune Design Corp.)

Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and...

Oct 18, 2011, 07:00 ET
Immune Design Corp.  (PRNewsFoto/Immune Design Corp.)

Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer

Immune Design Corp. (IDC) announced today that Guy F. Cipriani, MBA will be joining the company as its new Chief Business Officer.  In the...

Apr 27, 2011, 06:27 ET

Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer

Immune Design Corp. (IDC) announced today that Carlos V. Paya, MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May...

Oct 26, 2010, 04:00 ET

Immune Design Grants Adjuvant License to MedImmune

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer,...

Jul 26, 2010, 05:00 ET

Immune Design Corp. Raises $32 Million in Series B Financing

Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease...

Nov 23, 2009, 12:48 ET
A F IMMUNE DESIGN CORP. DR. BRUCE L.A. CARTER IMMUNE DESIGN CORP. DR. BRUCE L.A. CARTER

Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director. (PRNewsFoto/Immune Design Corp.)[DB]
 SEATTLE, WA UNITED STATES
 11/20/2009

Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director

Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track...

Nov 20, 2008, 11:00 ET

IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant

IDRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which...

Jun 23, 2008, 01:00 ET

Immune Design Announces $18 Million Series A Financing

SEATTLE, June 23 /PRNewswire/ -- Immune Design, a new generation vaccine company built on emerging understanding of the human immune system,...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Analysts Review